Close
Nordic 9Nordic 9

Michiel Seerden (investor - Angel Investor)

Netherlands
See something wrong or missing? Let us know
Offices:Eindhoven
Average round investment:3.5M USD
Average number per year:1.0
Distribution: 2025 (1)
Portfolio companies: Finland Arivin Therapeutics
Mostly invests in: Finland Finland (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Michiel Seerden

Name Criteria
Belgium Cascara Ventures
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Luxembourg ACME Investments
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Italy Italian Angels for Growth
81%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Finland
  • Average number of deals per year: 4.6
  • Active last 12 months: Yes
Sweden Albert & Anna Göranssons Minne
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Good Growth Capital
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Hans Frykman
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Johan Markman
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Mikael Lönn
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Poland Montis Capital
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Rhia Ventures
80%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top